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ABSTRACT 
A variety of huge number of phytoconstituents isolated from the parts of plant or whole plants having the wide spectrum of pharmacological 
activity. But these phytoconstituents, despite having excellent in vitro bioactivity, but fails to show no in vivo activity  actions, due to their 
limited lipid or aqueous  solubility, Improper molecular size, improper permeation through biological mucosa or destruction in gastric or  gut 
environment. So that the potential use of these herbal based drugs are limited due to their poor absorption and poor bioavailability after topical 
or oral administration. Over the past century, the great advancement has been made for development of novel drug delivery systems (NDDS) of 
phytoconstituents and herbal extracts such as Nanotechnology based formulation, liposomes, niosomes, transferosomes, ethosomes  
Phytophospholipid complex (phytosomes) and microparticle, etc has been developed. Novel potential phytophospholipid complexation 
methods have been developed by the formulation researcher to enhance the therapeutic activity of plant based drugs. In this method 
complexation of phytoconstituents with phospholipids in different molar ratio results into the development of novel herbal drug delivery 
system “phytophospholipid complex”. From the earlier research the formulation scientists have been proved that phytophospholipid complex 
show better pharmacokinetic and pharmacological profile than conventional herbal extracts. This review article highlights about the 
phospholipd as a carrier, current and future scenario of phytophospholipid complex and its potential application in hepatoprotection. 
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INTRODUCTION  
Naturally occurring herbal drugs or Plants based derived 
drugs gained advantages and popularize in the global 
markets as a safer and effective substitutes of synthetic 
drugs which are considered to be full of adverse and toxic 
interactions. Currently, one-third to approximately one-half 
of presently available drugs are generally derived from 
plants or other natural sources 1, 2. 
 However, huge number plant active molecules isolated from 
plants are poorly absorbed by oral route, which limits their 
widespread application3, 4. The poor absorption of these 
phytocompounds results is mainly due to two inherent 
properties. First, the multi-ring structures of natural 
compounds are too large that limits the absorption of drug 
by passive diffusion or non-active absorption. Second, the 
poor aqueous or lipid solubility of these phyto compounds 
prevents the permeation of drug through the outer 
membrane of gastrointestinal cells 5, 6. Active 
phytoconstituents isolated from natural sources have been 
shown excellent in vitro pharmacological activity, but poor in 
vivo performance. So the past few decades, a great 
advancement and attention has been focused on the 
development of herbal novel drug delivery system (HNDDS). 
However, the poor oral bioavailability of naturally occurring 
or plant active principles has become the challenging task for 
formulation researchers. further It has been observed from 
the past research that poor bioavailability of these 
compounds are mainly due to the low water or lipid 
solubility, high molecular weight/size and poor plasma 
membrane permeability 3,7,8. Moreover the standardized 
extracts when given by oral route, lose some of their 
constituents in the presence of gastric fluids 5. 
In herbal drug formulation research, several novel delivery 
systems have been developed such as nanotechnology based 
delivery like nanoparticle, lipid based system like liposomes, 
niosomes, transferosomes, ethosomes, phytophospholipid 
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complexes etc. These novel carrier systems have a number of 
advantages for naturally occurring active principles like 
solubility enhancement and improvement of bioavailability, 
protection of drug from toxicity, enhancement of therapeutic 
activity, stability improvement of formulation, improving 
tissue macrophages distribution, sustained drug delivery, 
protection of drug from degradation through physical and 
chemical environment etc. 9 
So the novel technique has been developed by complexing 
plant actives with phospholipids, this is  one of the most 
successful methods for improving bioavailability and 
therapeutic potential of a number of poorly absorbed 
naturally occurring phytoconstituents and their derivatives . 
The phytophospholipid complexation method was first 
developed in the year 1989 in Italy by chemically interaction 
of phytoconstotuents especially polyphenolic extracts with 
phospholipids containing phosphatidyl choline. The formed 
complex markedly improves the bioavailability of the 
polyphenolics when it compared with the bioavailability of 
pure drug/ extract 10. 
This technique employed by utilizing the phospholipid 
molecules specially, containing phosphotidylcholine to form 
complexes with phyto constituents which results in 
improvement of the membrane permeability, water–oil 
partition coefficient and hence the bioavailability of these 
drugs 11, 12. The incorporation of water soluble drugs into 
their phospholipid complexation, enhanced their 
bioavailability by increasing permeation through the lipoidal 
biological membrane while the phospholipid complexation of 
poorly water soluble drugs improved their bioavailability by 
increasing their solubility in gastric fluids 13, 14. 
 
 
Figure-1 Structure of phytophospholipid molecule15 
ADVANTAGES OF PHYTOPHOSPHOLIPID COMPLEX  
 
Figure -2 Benefits of phytophospholipd complex 
 
PHYTOPHOSHOLIPID –  
there are many so straiges have been developed to improve 
the bioavailability and therapeutic efficacy of herbal drugs, 
but one of the novel method that is employed by  the 
complexation of herbal compounds with naturally occurring 
phospholipid molecules has arisen as a potential novel 
carrier system for improving the bio-absorption of poorly 
absorbed phytoconstituents. The phospholipid molecules 
have unique structural components which are similar to the 
lipid content of the mammalian cell membrane so that it 
becomes the highly compatible with the human 
physiological system 16.  
Phospholipids are lipids that contain phosphorus, a polar 
head potion and non-polar tail potion in their structural 
back bone.10 Phospholipids are amphiphillic in nature and 
have the characteristics of excellent biocompatibility 
because of the similar lipoid structure present in 
mammalian cell membrane. These unique properties of 
phospholipids make it more appropriate to be employed as 
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important pharmaceutical excipients and have versatile 
applications in development of novel carrier systems. 
The mammalian biological membrane constitutes by 
different classes of phospholipids, like phosphatidyl 
ethanolamine (PE), phosphatidylinositol (PI), 
phosphatidylcholine (PC), phosphatidic acid (PA), and 
phosphatidylserine (PS).17  
 
 
Figure 3- Structure of phospholipid 18 
 
phosphatidylcholine (PC) contains two neutral tail groups 
and a positive head group which contains an oxygen atom in 
the phosphate group that has a strong tendency to gain 
electrons, while nitrogen is to lose electrons. So this type 
molecular arrangement, makes PC miscible in both water 
and lipid environments.19 
 
 
Figure-4 Structure of phosphotidylcholine 20 
 
THE MAIN SOURCES OF PHOSPHOLIPIDS- 
According to the source phospholipids can be classified as 
natural phospholipids and synthetic phospholipids. 
Natural phospholipids 
In 1793, a complex aliphatic compounds was identified by  
Fourcroy.  In 1812, Uauquelin first discovered phospholipids 
in human brain. In 1846, firstly Gobley phospholipids from 
egg yolk. The term “lecithin” which is derived from the Greek 
lekithos was first used to describe a sticky orange material 
that is isolated from egg yolk. After 20 years, choline 
component in lecithin was determined 21. Phospholipids are 
widely distributed in animals and plants,and the main 
sources are vegetable oils (e.g. soybean, cotton seed, corn oil, 
sunflower and rapeseed) and animal tissues (e.g. egg yolk 
and bovine brain). In terms of production, egg yolk and 
soybean are the most important sources for phospholipids 22. 
However, soybean and egg yolk phospholipids are differ in 
their contents and species of phospholipids, mainly 
including:  
1) Egg yolk lecithin contains a higher amount of PC. 
2) Phospholipids present in egg yolk contains long chain 
polyunsaturated fatty acids of N-6 and N-3 series, 
primarily arachidonic acid (AA) and docosahexaenoic 
acid (DHA), which are absent in soybean lecithins;  
3) Animal lecithins have characteristic of the presence of 
sphignomylins SM 23.  
4) The saturation level of egg yolk lecithins is higher than 
that of soybean lecithins 24, so their oxidative stability is 
better than that of soybean lecithins. 
5) In the egg yolk phospholipids, saturated fatty acid is 
usually at sn-1 position, and unsaturated fatty acid is at 
sn-2 position 25, while for soybean lecithin, SN-1 and 
SN-2 position can be both unsaturated fatty acids. For 
example, dilinoleoylphosphatidylcholine (DLPC) is the 
main component of soybean phosphatidylcholine (SPC) 
26. 
Synthetic phospholipids- Scientists and researcher mainly 
focus on chemical synthesis to obtain single component with 
defined structure and configuration 27. The synthesis of 
phospholipids can be divided into semi synthesis and total 
synthesis. Semi-synthesis method of glycerol-phospholipids 
is obtained by changing the head or tail groups or both on 
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the basis of natural phospholipids and it takes less reaction 
steps as compared to total synthesis.  
 The semi-synthetic methods for glycerophospholipids 
mainly include:  
1) Hydrogenation of double bond of natural phospholipid 
to obtain the saturated phospholipids that have a high 
melting point and oxidation stability;  
2) Acylation of SN-glycero-3- phosphocholine (GPC) 
obtained by deacylation of natural PC with activated 
acyl derivative can get the desired PC;  
3) Phospholipase D catalyzes glycerophospholipids to 
generate the phosphatidic acid (PA), and the hydroxy-
containing acceptors such as glycerol and serine can 
attach to PA, which can converse the choline head 
group into various phosphorylated alcohol head 
groups. 
The total synthesis of glycerophospholipids involves the 
formation of ester or ether bonds linking apolar moieties to 
glycerol backbone, and the attachment of polar head group. 
The synthetic glycerophospholipids have the advantages of 
single component and stable property.25. 
The procedure for semi-synthesis of sphignomylin SM 
involves the deacylation of the natural SM extracts (obtained 
primarily from bovine brains) results in the formation of  
sphingosylphospocholine further  acylated to SM by using 
the fatty acid of choice. It has been found that during the 
reaction step of deacylation-reacylation, a significant amount 
of the L-threo stereoisomer is formed. So that the final 
product contains the mixture of D-erythro and L-threo 
stereoiomers 28. 
The total synthesis of SM is considerably more complex than 
that of the glycerophospholipids. So that there are only few 
studies on the fully synthetic and stereochemically pure SM 
28.  The complete or total synthesis of SM includes the 
following steps: 1) the synthesis of sphingosine, 2) the 
synthesis of ceramide (N-acylsphingosine), 3) the synthesis 
of SM 29. 
HEPATOTOXICITY AND HEPATIC DAMAGE- 
The liver is a vital, largest visceral organ for metabolism and 
elimination of drugs. Its strategic location and 
multidimensional functions support almost every other 
organ in the body. 30, 31 
It also regulates various functions in the body, like 
metabolism, secretion, storage and detoxification. Hepatic 
diseases are now a day’s very common in developed and 
developing country. Liver damage is usually associated with 
the distortion of some of above mentioned functions. After 
intestinal absorption of drug, the portal vein supplies blood 
to the liver. So liver is directly exposed to elevated amount of 
toxic agents 32,33 
Some drugs, when taken in overdoses may cause liver injury 
for example acetaminophen. Chemicals, drugs or their 
metabolite that cause liver injury are called hepatotoxins 34.  
As per the literature search about 50% of all acute liver 
failure cases  represents a serious clinical problem, are due 
to drug-induced hepatotoxicity make it.Although the 
majority of cases of acute liver failure are due to intentional 
or unintentional misuse, 16% are idiosyncratic 35. Some 
examples of inorganic compounds may cause hepatotoxicity 
are arsenic, phosphorus, copper and iron. Certain naturally 
occurring plant toxins such as pyrrolizidine alkaloids, fungal 
toxins and bacterial toxins cause liver damage. 36. 
 Liver damage can also be caused by certain drugs, especially 
anti-tubercular drugs, general anesthetics, paracetamol and 
some anti-cancer drugs.  
Toxic hepatitis  a serious liver disease caused by severe 
adverse reaction to antituberculosis drugs, it usually initiates 
in the first few weeks of treatment along with liver necrosis, 
further results  to encephalopathy and death. 
 
 
Figure-5 .Structure of some hepatotoxic agent37 
Cirrhosis (formation of fibrous tissue in liver) caused by 
excessive consumption of alcohol,is a common occurrence in 
modern life style. Sometimes Liver can also be damaged by 
some chemicals such as galactosamine and chloroform 38.  
It is not necessary that liver toxicity occurs from direct 
toxicity of the primary compound but also from reactive 
metabolite or immunologically-mediated response. This can 
affect hepatocytes, biliary epithelial cells and liver 
vasculature 39, 40.  
Hepatotoxic response produced by chemicals or drugs or 
metabolite and toxins mainly depends upon the nature of 
toxicant, concentration gradient of the toxicant and liver 
enzymes level in blood .41 
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MECHANISM OF HEPATOTOXICITY 
Liver is the main vital organ for metabolism and elimination 
of drugs. 
Most of the drugs (oral) and xenobiotics are lipophilic which 
enables their easy absorption across intestinal membranes. 
They are rendered hydrophilic via hepatic metabolism and 
are easily excreted. Exogenous products are metabolized in 
the liver mainly through phase I and II reactions 42. The 
hepatic metabolism involves Phase I and Phase II reactions. 
Phase I involves oxidative, reductive, hydroxylation and de-
methylation pathways, primarily by way of the cytochrome 
P-450, the most important family of metabolizing enzymes 
system which is located in the endoplasmic reticulum in the 
liver. Phase I reactions mostly produce toxic intermediates 
which are transformed to non-toxic compounds by phase II 
reactions, usually considered as detoxification pathways. 
Phase II reactions involve the conjugation of chemicals with 
hydrophilic moieties such as glucuronide, sulfate or amino 
acids and lead to the formation of more water-soluble 
metabolite which can be excreted easily 43. Further Phase II 
reaction implicates glutathione which can covalently bind to 
toxic intermediates by glutathione-S-transferase. However, 
this phase can also lead to the formation of unstable 
precursors of reactive species that can cause hepatotoxicity 
44, 45, 46.  
 
HEPATOTOXINS/ 
INTERMEDIATE  
METABOLITE/
NONPOLAR
TOXIC IN NATURE 
POLAR MOLECULE 
LESS TOXIC IN 
NATURE 
PHASE II REACTION
BIOTRANFORMATION 
LIVER  
NON POLAR MOLECULE 
CONVERT INTO 
POLAR MOLECULE   
POLAR MOLECULES 
EASILY 
ELIMINATED FROM BODY 
PHASE I REACTION
BIOTRANSFORMATION
LIVER 
 
Figure -6 Metabolisms of hepatotoxins /xenobiotics in liver. 
TARGETING OF PHYTOLIPID BASED SYSTEM  
Phospholipids are the main source of phosphatidylcholine 
and choline, both the molecules of phospholipids liquefy the 
fat dumped inside the liver in the case of hepatic steatosis or 
fatty liver and also show some other hepatoprotective 
effects47. From the literature survey it was found that soya 
phospholipids are hepatoprotective in nature and prevent 
liver damage by alcohol, drugs abuse or drug induced and 
other toxins 48. They have also been reported to aid in 
clearance of serum cholesterol and increase circulating HDL 
levels in plasma 49. 
Targeting of phyto molecules at a particular site or specific 
organ is a very challenging task for the researchers that for 
therapeutic response it is necessary that specified amount of 
drug should reach to the target site to and retain for the 
desired duration. However, Phyto-lipid based vesicle system 
facilitates the liver targeting (Figure 1) by increasing the 
solubility in the bile salts. The targeting can also be achieved 
by attaching ligand in the site with right orientation for 
binding to the target receptors e.g. Monoclonal antibodies 
must bind to the drug carrier  system with their Fc part, so 
that their antigen binding site (Fab) is free to interact with 
the antigenic 50,51,52 
 
 
Figure-7- Targeting of drug to parenchymal cells (hepatocytes) of liver using ligand - 1 PC head - 2-Phyto-vesicles 3- Ligand 
molecule, 4- PC tail 53 
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HEPATOPROTECTIVE POTENTIAL OF 
PHYTOPHOSPHOLIPID COMPLEX 
Pifferi (1991) concluded that silybin phospholipd complex 
given orally shows higher pharmacological activity in animal 
models of hepatic injury. Further result obtained that oral 
bioavailability and specific organ targeting nature of silybin 
phospholipd was found to be much greater than that of 
silybin administered as a component of silymarin54. 
Bombardelli et al. (1991) investigated that Silymarin, 
standardized mixture of flavanolignans isolated from the 
fruits of S. marianum was complexed with phospholipids. 
The complex showed much higher specific activity and a 
long lasting action than the components, with respect to per 
cent reduction of odema, inhibition of myeloperoxidase 
activity, antioxidant and free radical scavenging properties55. 
Conti et al. (1992) tested IdB1016 (silybin-
phosphatidylcholine) in rodents in different models of liver 
damage. After oral administration, silipide exhibited a 
significant and dose related protective effect against the 
hepatotoxicity induced by CCl4, praseodymium, ethanol and 
galactosamine. Unlike the silybin and Phosphatidylcholine, 
in the same dose the complex IdB1016 showed protective 
activity against paracetamol induced hepatotoxicity 56. 
Buzzelli et al. (1993) a pilot study was carried out for liver 
protective effect of silybin-phosphatidylcholine complex 
(IdB 1016) in chronic active hepatitis (CAH), and it was 
found that IdB1016  that complex formulation improve liver 
function test related to hepatocellular necrosis and/or 
increased membrane permeability in patients offered by 
CAH 57. 
Carini et al. (1992) corelated that the addition of increasing 
concentrations of IdB 1016 to isolated rat hepatocytes 
caused a dose-dependent inhibition of lipid peroxidation 
induced by cumene hydroperoxidase. Further it was 
concluded that IdB 1016 acted as potentially useful 
protective agent against free radical mediated toxic liver 
injury 58.  
Vailati et al. (1993) performed a phase-II randomized open 
trial to clinically evaluate the dose response relationship of 
IdB 1016 in patients with viral or alcoholic hepatitis. It was 
found that treatment with IdB 1016 showed improvement in 
dose dependent manner59. 
Busby et al. (2002) concluded from the study that silymarin 
phytosome showed a better hetoprotectant activity from 
ethanol-induced behavioral deficits than pure silymarin 60.  
Tedesco et al (2004) investigated silymarin loaded 
phytosome exert better antihepatotoxic activity than 
silymarin alone and it can also provide protection against 
the toxic effects of aflatoxin B1 on performance of broiler 
chicks 61. 
Maiti et al.,(2005) developed the quercetin–phospholipid 
complex by a simple and reproducible method and also 
showed that the formulation exerted better therapeutic 
efficacy than the molecule in rat liver injury induced by 
carbon tetrachloride62. 
Yanyu et al (2006) developed the silymarin loaded 
phytosome and studied pharmacokinetic parameters in 
rats.from the study it was found that  the bioavailability of 
silybin-phospholipid complex was increased remarkably 
after oral administration than the silybin alone in rats .this is 
due to increase lipophilic property of silybin-phospholipid 
complex and further improvement of the biological effect of 
silybin 63. 
CONCLUSION  
The challenges regarding phytopharmaceuticals in the area 
of liver related problems is very much in demand to 
generate new therapeutic entity or dosages form 
development. A lot of phytocomponds have been isolated 
and some are in pipeline but all these having excellent in 
vitro action but fails to produce in vivo because of their 
physicochemical inherent property which limits the 
opportunity to generate carrier system containing plan 
components. So phyto-phospholipid complexation 
approache has offered a preparation of herbal drugs that 
have sufficient lipid penetrability, higher concentration at 
the site of absortion  and sustained therapeutic levels in 
plasma with a slower rate of elimination. 
Apart from this, the unique carrier system utilized that is 
Phospholipids, as one of the most promising novel material, 
which can be exploited intelligently and effectively to target 
liver related disorders and diseases as well as its protection. 
The prepared complex increases the solubility of 
phytocompound in water or lipids make them excellent 
carrier system for improving the bioavailability of herbal 
drugs. 
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